Norstella’s Post

Explore the forefront of pharmaceutical innovation with Norstella’s June roundup, featuring cutting-edge insights from industry trailblazers and learn about the latest news and updates from our brands. Check out the links below. 👇 Norstella announced a new strategic partnership with Atropos Health, the pioneer in translating real-world clinical data into high-quality, personalized, real-world evidence for care. Read about the benefits for Panalgo and Citeline customers: https://ow.ly/Ouay50Ss452 Citeline Regulatory's TrialScope Disclose has been the leader in helping clinical trial sponsors prepare their studies for public disclosure for over a decade. With the addition of the Core Data platform, it continues to provide cutting-edge disclosure technology to enable seamless regulatory compliance. Learn more: https://ow.ly/LZSq50Ss44Z Are you ready to look at the pharma landscape through a long-range lens? Evaluate Ltd has just released new forecasts out to 2030. Register for the World Preview Webinar 2024 Pharma’s Growth Boost: https://ow.ly/V6Jm50Ss450 Do you need a primer on market access? In this free ebook from MMIT (Managed Markets Insight & Technology) for pharma, you can learn how to understand and influence payer policies, improve coverage and communicate with HCPs. https://ow.ly/XKEN50Ss45i Understanding open and closed claims is critical. In this eBook, Panalgo's Executive Director of Solutions, Margaret (Meg) Richards, PhD, MPH, uncovers the nuances of open vs. closed claims: https://ow.ly/7I0k50Ss459 The Dedham Group stands as the premier pharmaceutical consultancy firm, renowned for its expertise in crafting, executing, and overseeing Patient Support Programs. Learn about The Dedham Group’s customized solutions that drive success: https://ow.ly/y1FG50Ss457 Follow our brands to stay up with the latest news, insights, and updates! #Pipeline2Patient #FollowNorstella

Partnering with patients to develop clinical trials and medicines that delivers the most relevant clinical outcomes and supports sustainable healthcare systems.    At the Measuring Patient Engagement Summit, I will discuss our Patient Engagement Impact Measurement Framework that we co-created with a patient council. A standardized approach across the pharmaceutical industry that would support evidence generation and best practice sharing, so join this session to see how you could adapt and apply this approach to your own work. I will: - Introduce the framework and how it is connected to strategy across the medicines lifecycle  - Summarise the challenges and learnings we’e had so far from developing the framework and implementing the metrics - Give examples for key patient engagement activities such as patient life experience; patient-focused drug development, patient support programs.   Only together we will make patient voice basics of medicine lifecycle, see you there!

🚀 The Power of Early Evidence in Market Access 🚀 🌟 Did you know the average cost of developing a new drug is a staggering $1.3 billion? Despite this investment, many new treatments struggle to achieve commercial success due to stringent evidentiary requirements from healthcare payers. 🔍 Our latest blog post delves into how evidence generation is crucial for overcoming these hurdles. Discover how an early evidence strategy, tailored to the diverse needs of regulators, payers, clinicians and patients, can pave the way for successful market access. Key insights include: ·       🔗 The disconnect between regulatory approval and successful market access ·       🎯 The importance of aligning clinical trial design with HTA and payer requirements ·       📊 Strategies for comprehensive evidence generation to support reimbursement 📖 Read the blog now via the link in the comments. Stay tuned for Part 2, where we explore the four pillars of an effective early evidence generation strategy! Author: Evangelos Vasileios Papastergios #MarketAccess #HTA #Pharmaceuticals #HEOR #RealWorldEvidence

I authored a guest piece in Clinical Leader about my conversation provoking perspectives when it comes to patient engagement implementation and what, from a outside perspective, industry should be working to develop to assure patient engagement continues to be a essential and fundamental part of drug development, not just a nice to have. "The pharmaceutical and healthcare industries are at a transformative juncture where patient engagement can be not just a buzzword but a driving force for positive change. Patient attendance and involvement in conferences and co-creation in publications signify a significant shift toward a more inclusive and patient-centered approach. However, to truly understand the impact of patient engagement and to foster greater adoption and change, industry needs to develop frameworks for measuring patient engagement value and share more comprehensive case studies that detail successful implementations throughout the pharmaceutical life cycle. By highlighting industry examples, we can inspire a collective commitment to making patient voices an integral part of every facet of healthcare and solidify its value to business and to patients’ lives." I invite others' perspectives and want this piece to encourage conversation, critical thinking, and inspire continued innovation. Check out the full article.

A really well-thought-out piece by my friend and colleague Ella Balasa. She's hit the nail on the head on many fronts. A lot of supporting and counter points and questions come to mind: 1. 🐌 In any slow-moving industry, it takes about a decade of conversations before meaningful adoption and possibly another decade before meaningful outcomes analysis. Think publishing and open access, for example. When I worked in publishing, every industry conference for over a decade had a panel on the future of open access. And I wondered what next and when. It's debatable where the pharma/healthcare industry currently stands on this idea-to-adoption-to-measurement timeline for patient engagement. Ella argues that we are past the conversation and closer to the implementation and measurement timepoints. But my question is how many pharma and medical conferences, apart from those that have "Patients as Partners" in their name, even have patients on the speaker agenda or as a category in their registration forms? 2. 🪟I love Ella's point about the need for transparency with patients regarding the commercial value and profitability of patient-centric initiatives. This is potentially controversial because the truth is there are MASSIVE numbers of patients who see pharma as entirely profit-making and are suspicious of the industry in general. On the contrary, there are also increasing numbers of reasonable business-savvy patients who understand the massive investments pumped into medicine development and the need for profitability. Which of these categories of patients are more likely to be attending medical conferences and reading these publications? Why not truly partner and brainstorm brass tacks with these more broad-minded patients who have the power to influence mindsets within their extended networks of patients? 3. 🛣️ While Ella's ask is for pharma companies at more advanced stages of patient engagement, I'd expand it to include those at all stages: - If you don't yet have patient representation in your conferences and publications, you're already 5 years behind. Step on it! - If you have succeeded in building out your patient engagement strategy, start implementing it and sharing best practices. - If you have been intrinsically implementing patient engagement at various levels, start measuring your outcomes and discussing them transparently with patients. - If you don't know how to involve patients, ask us! #patientengagement #patientcentricity #patientinvolvement #patientadvocates #healthcare #pharma

As I learn more about clinical trials and patient engagement initiatives for my research, it is very refreshing to read articles that push for a data-driven approach to selecting patient engagement initiatives, as this article from Ella Balasa does! We will hopefully get to read more case studies on this in the upcoming years! #patientengagement #clinicaltrials

Check out this informative new article from Ella Balasa on what the #clinicaltrial industry needs to be working on to cement #patientengagement as the cornerstone of drug development.

The discipline of patient-insight-driven medicines development is recognized a vital driver of innovation. By encouraging the measurement of patient engagement, we can understand the areas of greatest impact – to support meaningful focus, empowering patient advisors to make a difference and supporting sustainable value generation for the industry.   At the Measuring Patient Engagement Summit, I will discuss our Patient Engagement Impact Measurement Framework that we co-created with a patient council. A standardized approach across the pharmaceutical industry would support evidence generation and best practice sharing, so join this session to see how you could adapt and apply this approach to your own work. I’m also looking forward to collaborating with industry peers across a workshop, panel, and roundtable to create a roadmap to standardized metrics and reporting: -Align on how to harmonize measurement framework, tools, metrics -Define priority metrics for different activities, stakeholders and outcomes -Identify opportunities to and benefits of publicly sharing specific results   Hope to see you there, if not, get in touch to request my poster / presentation. 

Today at SfEE Summit; value in Pharma needs to be redefined! In today's rapidly evolving healthcare landscape, it has become increasingly clear that the traditional definition of value in the pharmaceutical industry is no longer sufficient. It is time for us to rethink our approach and redefine what value truly means in the context of healthcare. True value in pharma should encompass a broader range of factors, including patient-centricity, real-world evidence & effectiveness, and long-term sustainability. By taking a more holistic view of value, we can better meet the needs of patients, providers, and payers alike.